Longitudinal prostate-specific antigen reference ranges: Choosing the underlying model of age-related changes

Longitudinal prostate-specific antigen reference ranges: Choosing the underlying model of age-related changes

Serial measurements of prostate-specific antigen (PSA) are used as a biomarker for men diagnosed with prostate cancer following an active monitoring programme. Distinguishing pathological changes from natural age-related changes is not straightforward. Here, we compare four approaches to modelling a...

Bibliografske podrobnosti
Main Authors:	Simpkin, A, Metcalfe, C, Martin, R, Lane, J, Donovan, J, Hamdy, F, Neal, D, Tilling, K
Format:	Journal article
Jezik:	English
Izdano:	SAGE Publications 2013

Podobne knjige/članki

Investigating the prostate specific antigen, body mass index and age relationship: is an age-BMI-adjusted PSA model clinically useful?
od: Harrison, S, et al.
Izdano: (2016)

Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy?
od: Macefield, R, et al.
Izdano: (2009)

Predictors of attendance for prostate-specific antigen screening tests and prostate biopsy.
od: Avery, K, et al.
Izdano: (2012)

Predictors of attendance for prostate-specific antigen screening tests and prostate biopsy
od: Avery, K, et al.
Izdano: (2012)

Seasonal variation in prostate-specific antigen levels: A large cross-sectional study of men in the UK
od: Down, L, et al.
Izdano: (2011)

Seasonal variation in prostate-specific antigen levels: a large cross-sectional study of men in the UK.
od: Down, L, et al.
Izdano: (2011)

ASSOCIATION OF ANTHROPOMETRIC AND LIFESTYLE FACTORS WITH PROSTATE SPECIFIC ANTIGEN (PSA) TRAJECTORIES IN MEN WITH LOCALISED PROSTATE CANCER UNDERGOING ACTIVE MONITORING
od: Burton, A, et al.
Izdano: (2011)

Prostate-specific antigen testing and prostate biopsy: are self-reported lower urinary tract symptoms and health-related quality of life associated with the decision to undergo these investigations?
od: Avery, K, et al.
Izdano: (2008)

Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen
od: Harrison, S, et al.
Izdano: (2020)

Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts.
od: Tilling, K, et al.
Izdano: (2010)

Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK.
od: Brindle, L, et al.
Izdano: (2006)

Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study
od: Young, GJ, et al.
Izdano: (2017)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study
od: Rosario, D, et al.
Izdano: (2012)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study.
od: Rosario, D, et al.
Izdano: (2012)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: Prospective evaluation within ProtecT study
od: Rosario, D, et al.
Izdano: (2012)

Age-Related Prostate Specific Antigen Reference Ranges in Healthy Northern Iranian Men
od: Shahrzad Rahimifar, et al.
Izdano: (2018-03-01)

Age-specific reference ranges of prostate-specific antigen in the elderly of Amirkola: A population-based study
od: Hosseini Seyed Reza, et al.
Izdano: (2021-04-01)

Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer.
od: Moore, A, et al.
Izdano: (2009)

Age-specific Reference Range of Prostate-specific Antigen among Indian Men: A Retrospective Observational Study
od: Mamatha T. Shenoy, et al.
Izdano: (2021-01-01)

Reference Ranges of Age-Related Prostate-Specific Antigen in Men without Cancer from Beijing Area.
od: Xin Liu, et al.
Izdano: (2013-11-01)

Associations of folate, vitamin B12, homocysteine, and folate-pathway polymorphisms with prostate-specific antigen velocity in men with localized prostate cancer.
od: Collin, S, et al.
Izdano: (2010)

Prostate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English cities.
od: Williams, N, et al.
Izdano: (2011)

Prostate-specific antigen testing rates remain low in UK general practice: A cross-sectional study in six English cities
od: Williams, N, et al.
Izdano: (2011)

Prostate cancer detection in men aged 45-49 years in the UK protect (prostate testing for cancer and treatment) trial
od: Hamdy, F, et al.
Izdano: (2006)

Serum insulin-like growth factor-I is positively associated with serum prostate-specific antigen in middle-aged men without evidence of prostate cancer.
od: Oliver, SE, et al.
Izdano: (2004)

Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study.
od: Burton, A, et al.
Izdano: (2013)

Development, validation and evaluation of an instrument for active monitoring of men with clinically localised prostate cancer: systematic review, cohort studies and qualitative study
od: Andrew J Simpkin, et al.
Izdano: (2015-07-01)

A comparison of methods to generate adaptive reference ranges in longitudinal monitoring.
od: Davood Roshan, et al.
Izdano: (2021-01-01)

Association of diabetes mellitus with prostate cancer: nested case-control study (Prostate testing for cancer and treatment study).
od: Turner, E, et al.
Izdano: (2011)

Experiences and decision processes during PSA testing and prostate biopsy: A qualitative study
od: Avery, K, et al.
Izdano: (2007)

ASSOCIATIONS OF SEXUAL DYSFUNCTION WITH LOCALIZED AND ADVANCED PROSTATE CANCER: A CASE-CONTROL STUDY NESTED WITHIN THE UK POPULATION-BASED PROTECT (PROSTATE TESTING FOR CANCER AND TREATMENT) STUDY
od: Collin, S, et al.
Izdano: (2009)

The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group.
od: Vickers, A, et al.
Izdano: (2010)

The protect trial - Evaluating the effectiveness of treatments for clinically localised prostate cancer and associated molecular and genetic epidemiology studies
od: Lane, J, et al.
Izdano: (2007)

Associations of sexual dysfunction symptoms with PSA-detected localised and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study.
od: Collin, S, et al.
Izdano: (2009)

Age-specific serum prostate specific antigen ranges among apparently healthy Nigerian men without clinical evidence of prostate cancer
od: Stephen O Ikuerowo, et al.
Izdano: (2016-01-01)

The Probability of Metastases Within Different Prostate-specific Antigen Ranges Using Prostate-specific Membrane Antigen Positron Emission Tomography in Patients with Newly Diagnosed Prostate Cancer
od: Wietske I. Luining, et al.
Izdano: (2024-01-01)

Ethics of clinical trials from bayesian perspective: randomisation to clinical trials may solve dilemma of treatment choice in prostate cancer.
od: Hamdy, F, et al.
Izdano: (2003)

THE PROTECT TRIAL - EVALUATING THE EFFECTIVENESS OF TREATMENTS FOR CLINICALLY LOCALISED PROSTATE CANCER
od: Lane, J, et al.
Izdano: (2009)

Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study.
od: Rosario, D, et al.
Izdano: (2008)

The ProtecT trial - Evaluating the effectiveness of treatment for clinically localised prostate cancer (ISRCTN20141297)
od: Lane, J, et al.
Izdano: (2004)